Lepor H, Knapp-Maloney G, Wozniak-Petrofsky J
Department of Urology, Medical College of Wisconsin, Milwaukee 53226.
Int J Clin Pharmacol Ther Toxicol. 1989 Aug;27(8):392-7.
The efficacy and safety of terazosin was evaluated in 28 normotensive patients with symptomatic benign prostatic hyperplasia (BPH) ranging in age between 52-72 years. The parameters utilized to assess the efficacy of terazosin included peak and mean urinary flow rate, micturition symptom score and the patients' global assessment of symptomatic improvement. The dose of terazosin was titrated to 5 mg/day over a one-month interval, provided significant adverse drug reactions were not observed. Twenty-two (79%) of the 28 patients completed the terazosin dose-titration study, 5 (18%) were withdrawn owing to adverse drug reactions and 1 (3%) was withdrawn owing to poor compliance. Overall, the mean systolic blood pressure, increased 3 mmHg (3%) and the diastolic blood pressure decreased 1 mmHg (1%). The peak and mean urinary flow rates increased 63% and 61%, respectively. The obstructive and irritative symptom scores decreased 62% and 33%, respectively. The improvements in urinary flow rates and symptom scores were clinically and statistically significant. Overall, 61% of the patients indicated that their voiding symptoms were markedly improved on terazosin and 64% of the participants have elected to voluntarily continue on terazosin indefinitely. In conclusion, terazosin represents a safe and effective treatment for symptomatic BPH.
在28名年龄在52至72岁之间、患有症状性良性前列腺增生（BPH）的血压正常患者中评估了特拉唑嗪的疗效和安全性。用于评估特拉唑嗪疗效的参数包括最大尿流率和平均尿流率、排尿症状评分以及患者对症状改善的总体评估。如果未观察到明显的药物不良反应，特拉唑嗪的剂量在一个月的时间内滴定至5毫克/天。28名患者中有22名（79%）完成了特拉唑嗪剂量滴定研究，5名（18%）因药物不良反应退出，1名（3%）因依从性差退出。总体而言，平均收缩压升高了3毫米汞柱（3%），舒张压降低了1毫米汞柱（1%）。最大尿流率和平均尿流率分别增加了63%和61%。梗阻性和刺激性症状评分分别降低了62%和33%。尿流率和症状评分的改善在临床和统计学上均具有显著意义。总体而言，61%的患者表示服用特拉唑嗪后排尿症状明显改善，64%的参与者选择无限期自愿继续服用特拉唑嗪。总之，特拉唑嗪是一种治疗症状性BPH的安全有效的药物。
